Oral arsenic trioxide for newly diagnosed APL
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 study tests an oral form of arsenic trioxide in people newly diagnosed with APL (a specific leukemia subtype). It aims to see how well this frontline treatment works and whether it can be given safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed APL with a specific gene change, or AML with a related RARA gene change
- You can follow all study visits, tests, and treatment rules
- You can and will sign informed consent (choose to join after learning about the study)
- Your overall health/function is not too limited (ECOG score 2 or less)
- Your heart, liver, and kidney tests meet safety cutoffs (heart rhythm, liver enzymes/bilirubin, and kidney filtration)
- If you can become pregnant: you must not be pregnant or breastfeeding before starting
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an oral version of arsenic trioxide works as well as the IV version for people with a certain type of leukemia called APL. It aims to confirm that taking the drug by mouth has similar safety and effectiveness.
This Phase 2 study tests a treatment approach for children and teens newly diagnosed with acute promyelocytic leukemia (APL) that is confirmed by a specific lab genetic change. It may help improve outcomes, but it requires meeting several safety and test-confirmation criteria.
This trial tests a new drug, QTX-2101, in people with acute promyelocytic leukemia (APL) that is low- or intermediate-risk. The study aims to see if the drug works and is safe for those who qualify.
This trial tests a combination of oral medications, including arsenic trioxide, venetoclax, and a chemotherapy agent (azacitidine or decitabine), for people with certain blood cancers (AML, MDS, or CMML) that have a TP53 gene mutation. The goal is to see if this pill-based treatment can help control the cancer.
This trial tests a combination of oral arsenic and ATRA for people newly diagnosed with acute promyelocytic leukemia (APL). It aims to see if this drug combo can treat the disease effectively without standard chemotherapy.
This trial tests if combining interferon-α with arsenic trioxide (ATO) can help people whose acute promyelocytic leukemia (APL) has stopped responding to arsenic treatment. If you have this type of leukemia that came back or didn't get better after arsenic therapy, this study may offer a new option.
Hear when a new Acute Promyelocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.